GoodMood Holdings, a Beijing-based digital mental healthcare company, has raised nearly $45 million (approximately RMB 300 million) in a financing round backed by Imeik Technology, CSC Financial Capital, Wuxi Binhu Industrial Group, Shandong Development and Unifuture Capital.
The financing was initially announced in September 2026, with the company issuing a further international announcement on October 29, 2026. The company plans to use the capital to develop its artificial intelligence capabilities, expand psychiatric and mental healthcare services, establish additional specialty clinics and support international expansion.
Founded in 2016 by Chen Guanwei, who serves as chairman and CEO, GoodMood Holdings operates a mental healthcare platform combining digital medical services, psychiatric specialists, physical clinics and enterprise mental health programmes.
The company operates two principal brands. Haoxinqing provides online medical consultations, specialist psychiatric services and workplace mental health programmes in China. MoodVia is a consumer-focused mental health application offering AI-powered mood tracking, personalised interventions based on cognitive behavioural therapy (CBT) and dialectical behaviour therapy (DBT), and access to licensed therapists.
GoodMood integrates AI into clinical workflows, including patient assessments, screening, triage, clinician support and follow-up care. Its service model connects online consultations with in-person treatment and longer-term mental health management.
According to the company’s October announcement, its platform had more than 14 million registered users and over 600 enterprise and institutional clients as of December 31, 2025. It also reported more than 134,000 registered clinicians in 2026.
Before the latest financing, GoodMood had completed six funding rounds. These included a Series C round of approximately RMB 200 million ($31 million) in 2021 led by ByteDance. Previous investors also included Nhwa Pharmaceutical, CITIC Medical Fund, Fosun Health and KIP.
The company has begun developing partnerships in other Asian markets and is exploring further opportunities in Japan and Malaysia, with Europe and the United States among its longer-term expansion targets.
The new funding will support GoodMood’s efforts to expand its clinical services and apply AI across mental healthcare delivery while developing its international operations.
